drug
tozinameran
Marketedupdated 3mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tozinameran
- —Secondary Databased Post-marketing Surveillance Study of BNT162b2
- —Korea Comirnaty Post-marketing Surveillance
- phase3Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
- phase2A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
- phase2Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
- phase2A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
- phase2A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
- phase4Anti-viral Action Against Type 1 Diabetes Autoimmunity
News(6)
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 9d ago
- Pfizer expands multibillion-dollar cost-cutting planHatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.biopharma_dive · 10d ago
- BioNTech cuts sales forecast on slumping demand for COVID-19 vaccineLower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.biospace · 10d ago
- Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructureThe additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…biospace · 10d ago
- BioNTech taps Sobi executive Oelkers as its next CEOGuido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.biopharma_dive · 11d ago
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 11d ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that